These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

529 related items for PubMed ID: 17512451

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Bevacizumab in the treatment of breast cancer.
    Koutras AK, Fountzilas G, Makatsoris T, Peroukides S, Kalofonos HP.
    Cancer Treat Rev; 2010 Feb; 36(1):75-82. PubMed ID: 19932567
    [Abstract] [Full Text] [Related]

  • 4. Bevacizumab in the treatment of metastatic breast cancer.
    Traina TA.
    Oncology (Williston Park); 2009 Apr 15; 23(4):327-32. PubMed ID: 19476261
    [Abstract] [Full Text] [Related]

  • 5. Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer.
    Damasceno M.
    Curr Opin Oncol; 2011 Apr 15; 23 Suppl():S3-9. PubMed ID: 21490481
    [Abstract] [Full Text] [Related]

  • 6. [Angiogenesis and breast cancer].
    Bachelot T, Ray-Coquard I, Cassier P, Blay JY.
    Bull Cancer; 2007 Jul 15; 94 Spec No():S203-10. PubMed ID: 17846006
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Antiangiogenic agents in breast cancer.
    Salter JT, Miller KD.
    Cancer Invest; 2007 Oct 15; 25(7):518-26. PubMed ID: 18027149
    [No Abstract] [Full Text] [Related]

  • 9. Breast tumour angiogenesis.
    Fox SB, Generali DG, Harris AL.
    Breast Cancer Res; 2007 Oct 15; 9(6):216. PubMed ID: 18190723
    [Abstract] [Full Text] [Related]

  • 10. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer.
    Los M, Roodhart JM, Voest EE.
    Oncologist; 2007 Apr 15; 12(4):443-50. PubMed ID: 17470687
    [Abstract] [Full Text] [Related]

  • 11. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.
    Ferrara N, Hillan KJ, Novotny W.
    Biochem Biophys Res Commun; 2005 Jul 29; 333(2):328-35. PubMed ID: 15961063
    [Abstract] [Full Text] [Related]

  • 12. Drug insight: antiangiogenic therapies for gastrointestinal cancers--focus on monoclonal antibodies.
    Reinacher-Schick A, Pohl M, Schmiegel W.
    Nat Clin Pract Gastroenterol Hepatol; 2008 May 29; 5(5):250-67. PubMed ID: 18382435
    [Abstract] [Full Text] [Related]

  • 13. Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact.
    Elice F, Rodeghiero F.
    Thromb Res; 2010 Apr 29; 125 Suppl 2():S55-7. PubMed ID: 20434006
    [Abstract] [Full Text] [Related]

  • 14. [Anti-VEGF therapy with bevacizumab in breast cancer].
    Tóth J, Gonda A, Szántó J.
    Lege Artis Med; 2008 Oct 29; 18(10):669-73. PubMed ID: 19227609
    [Abstract] [Full Text] [Related]

  • 15. Vascular endothelial growth factor and bevacitumab in breast cancer.
    Bando H.
    Breast Cancer; 2007 Oct 29; 14(2):163-73. PubMed ID: 17485901
    [Abstract] [Full Text] [Related]

  • 16. Angiogenesis of breast cancer.
    Schneider BP, Miller KD.
    J Clin Oncol; 2005 Mar 10; 23(8):1782-90. PubMed ID: 15755986
    [No Abstract] [Full Text] [Related]

  • 17. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
    Chase JL.
    Pharmacotherapy; 2008 Nov 10; 28(11 Pt 2):23S-30S. PubMed ID: 18980549
    [Abstract] [Full Text] [Related]

  • 18. Overview of anti-VEGF therapy and angiogenesis. Part 1: Angiogenesis inhibition in solid tumor malignancies.
    Ellis LM, Rosen L, Gordon MS.
    Clin Adv Hematol Oncol; 2006 Jan 10; 4(1):suppl 1-10; quz 11-2. PubMed ID: 16562372
    [Abstract] [Full Text] [Related]

  • 19. [Anti-angiogenic treatment and colorectal cancer].
    André T, Tournigand C, Abbas F, Louvet C, de Gramont A, Gercor (French Oncology Research Group).
    Bull Cancer; 2007 Jul 10; 94 Spec No():S211-9. PubMed ID: 17846007
    [Abstract] [Full Text] [Related]

  • 20. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
    Guarneri V, Miles D, Robert N, Diéras V, Glaspy J, Smith I, Thomssen C, Biganzoli L, Taran T, Conte P.
    Breast Cancer Res Treat; 2010 Jul 10; 122(1):181-8. PubMed ID: 20361252
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.